According to studies, a new cancer vaccination may virtually double patient survival for several types of lung cancer.


According to a French biotechnology firm, their cancer vaccine successfully reduced the chance of mortality for certain lung cancer patients by 41%.


According to a French biotechnology company, a novel vaccination has been demonstrated to increase survival for persons with certain lung malignancies.

The Tedopi vaccination from Ose Immunotherapeutics has been proven to be successful in lowering death rates in some lung malignancies, the business stated in a statement on Monday.



In the US and Europe, lung cancer is the primary reason for cancer-related fatalities.

The findings of a phase 3 clinical study, the final step before a medicine can be launched, to assess the vaccine's therapeutic advantages were released in the Annals of Oncology publication.

Non-small cell lung cancer (NSCLC or adenocarcinoma), the most prevalent form of lung cancer and one that is "usually less sensitive to chemotherapy and radiation therapy," was given the vaccination to patients with advanced NSCLC.


41% less chance of dying
The research involved 219 individuals from nine European and American nations who had all displayed resistance to prior therapies. 80 individuals underwent treatment, whereas 139 patients received the vaccination.



Compared to patients who got chemotherapy, those who received Tedopi had a much greater survival rate and improved quality of life.

"A significant 41% reduction in the risk of death was observed, associated with an improved tolerance score and maintained quality of life," stated Professor Benjamin Besse, the study's primary author from the Gustave Roussy Institute.

In this experiment, the vaccine from Ose Immunotherapeutics was given as a third-line therapy after the patients had already undergone two different treatments.

In order to perhaps make this cancer vaccine available to difficult-to-treat patients who are failing treatment and have significant medical demands, Besse continued, "Further evaluation is clearly warranted in a second line of treatment of advanced and metastatic NSCLC."

According to Ose Immunotherapeutics, people with the HLA-A2 gene, which is present in nearly half of the population, respond well to the Tedopi vaccination.


After being provided every three weeks at first, it is then given every eight weeks for a year, then every 12 weeks.

The CEO of the firm, Nicolas Poirier, stated that the most recent outcomes of the various studies "highlighted the promise of this new therapeutic class of vaccines."



Modernizations in immunotherapy

Tedopi is a therapeutic, not preventative, cancer vaccine.

Therapeutic cancer vaccines work to hone the immune system's capacity to recognize and eradicate tumor cells with precision. In other words, they attack cancer by utilizing the patient's natural defense mechanism.

According to Cancer Research UK, research conducted during the pandemic "has accelerated the production of vaccines, specifically mRNA vaccines," which has helped the discipline of immunotherapy make significant strides throughout the 2010s.

Since then, a number of immunotherapeutic medications have been authorized, and research is currently underway. 

The UK government and BioNTech secured a contract earlier this year to start cancer vaccine studies and treat up to 10,000 patients by 2030.

Despite the high prices of the therapies, Market Future Insight projects that the worldwide market for cancer vaccines will be worth €22 billion in 2033.

The day after the study findings were revealed, the price of Ose Immunotherapeutics' shares increased by 60% on the Paris Stock Exchange.